https://www.selleckchem.com/pr....oducts/Aloxistatin.h
group versus 61 (30%) of 202 patients in the intravenous cisplatin group (p=0·01). Oral metronomic chemotherapy is non-inferior to intravenous cisplatin with respect to overall survival in head and neck cancer in the palliative setting, and is associated with fewer adverse events. It therefore represents a new alternative standard of care if current NCCN-approved options for palliative therapy are not feasible. Tata Memorial Center Research Administration Council. For the Hindi, Marathi, Gujarati, Kannada, Malayalam, Telugu, Oriya,
Like
Comment
Share
